Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) — Cash Flow Quality Index
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a Cash Flow Quality Index of -0.20x as of June 2023. Operating cash flow of €-64.53 Million is below net income of €321.70 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can Tianjin Zhong Xin Pharmaceutical Group C service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Tianjin Zhong Xin Pharmaceutical Group C cash conversion from operations.
Annual Cash Flow Quality Index for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
Year-by-year earnings quality comparison for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | €461.07 Million | €2.13 Billion | ▼ -47.8% |
| 2024 | 0.41x | €924.67 Million | €2.23 Billion | ▼ -40.6% |
| 2023 | 0.70x | €688.49 Million | €986.71 Million | ▼ -11.2% |
| 2022 | 0.79x | €677.25 Million | €861.79 Million | ▼ -29.1% |
| 2021 | 1.11x | €852.40 Million | €769.14 Million | ▲ +9.2% |
| 2020 | 1.01x | €671.42 Million | €661.70 Million | ▲ +28.1% |
| 2019 | 0.79x | €495.49 Million | €625.57 Million | ▲ +27.1% |
| 2018 | 0.62x | €350.14 Million | €561.68 Million | ▲ +7570.7% |
| 2017 | -0.01x | €-3.97 Million | €476.08 Million | ▼ -100.8% |
| 2016 | 0.99x | €417.77 Million | €422.42 Million | ▲ +23.8% |
| 2015 | 0.80x | €360.58 Million | €451.44 Million | ▼ -0.4% |
| 2014 | 0.80x | €286.85 Million | €357.80 Million | ▲ +32.1% |
| 2013 | 0.61x | €213.44 Million | €351.79 Million | — |